Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02445976 | Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. | completed | Phase 2 | 197 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01664923 | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer(STRIVE) | completed | Phase 2 | 396 | PfizerINDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02409212 | Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer(PANTERA) | completed | Phase 2 | 50 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00231842 | Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03804866 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | completed | Phase 2 | 14 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00087126 | Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01808222 | FACBC for Recurrent Prostate Cancer | completed | Phase 2 | 25 | David M. Schuster, MDOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT03042702 | A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer | completed | Phase 2 | 2 | Innovation Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01936363 | Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer | completed | Phase 2 | 65 | EMD SeronoINDUSTRY | 7 | Dec 12, 2018 | clinicaltrials |
| NCT00450463 | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00499408 | Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00038181 | Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02107430 | Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 62 | SOTIO a.s.INDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00006079 | Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00384839 | Vidaza to Restore Hormone Thx Prostate | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00599313 | Phase II Sunitinib Prog Met AIPC | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT01981122 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 52 | DendreonINDUSTRY | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01091103 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01547299 | Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 2 | Oct 23, 2018 | clinicaltrials |
| NCT01620710 | Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes(PRIAMOS) | completed | Phase 2 | 80 | Heidelberg UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01669798 | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 32 | AA SecordOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02153918 | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00942578 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00436956 | AZD2171 to Treat Prostate Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00634647 | Satraplatin and Prednisone to Treat Prostate Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | completed | Phase 2 | 67 | Astellas Pharma IncINDUSTRY | 4 | Oct 2, 2018 | clinicaltrials |
| NCT00030706 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Montefiore Medical CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer(NGR018) | completed | Phase 2 | 119 | AGC Biologics S.p.A.INDUSTRY | 2 | Sep 27, 2018 | clinicaltrials |
| NCT01270880 | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT01519414 | Tivantinib in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT02091050 | 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy | completed | Phase 2 | 60 | AC Camargo Cancer CenterOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00400517 | GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Feb 1, 2019source: clinicaltrials